Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer

S. J. Tan, Y. H. Juan, P. T. Fu, M. H. Yu, H. C. Lai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Management of patients with recurrent or advanced cervical cancer is a challenge. Concurrent chemotherapy has become the mainstay of treatment and platinum remains the most effective single agent. Combinations of other agents have not demonstrated significant advantages. The application of angiogenesis inhibitors such as bevacizumab, an antibody inhibiting vascular endothelial growth factor, in metastatic or advanced cervical cancer remains to be evaluated. We present the case of a patient with platinum-resistant recurrent cervical cancer treated with low-dose bevacizumab and carboplatin, with resultant improved disease progression and tolerable toxicity profiles.

Original languageEnglish
Pages (from-to)350-353
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume31
Issue number3
Publication statusPublished - 2010
Externally publishedYes

Keywords

  • Bevacizumab
  • Cervical cancer
  • Metronomic

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer'. Together they form a unique fingerprint.

  • Cite this